Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. - Wikidata - wikimedia - TriplyDB

Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.

Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.

http://www.wikidata.org/entity/Q35242884

about

Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3 Nuclear receptor corepressors and PPARgamma Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?Hydroxycinnamic acid derivatives: a potential class of natural compounds for the management of lipid metabolism and obesity Road to exercise mimetics: targeting nuclear receptors in skeletal muscle Perinatal overnutrition exacerbates adipose tissue inflammation caused by high-fat feeding in C57BL/6J mice 'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies PAS kinase is required for normal cellular energy balance PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism.Ablation of ARNT/HIF1beta in liver alters gluconeogenesis, lipogenic gene expression, and serum ketones Skeletal Muscle Nucleo-Mitochondrial Crosstalk in Obesity and Type 2 Diabetes.The contribution of visceral fat to improved insulin signaling in Ames dwarf mice.Nuclear receptors, mitochondria and lipid metabolism Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice.Role of Nuclear Receptors in Exercise-Induced Muscle Adaptations.Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of peroxisome proliferator-activated receptor gamma activation in mice.Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin.Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1 Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis.Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.Analysis of gene expression in pathophysiological states: balancing false discovery and false negative rates.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and beta cell failure.PPAR gamma and human metabolic disease Molecular Implications of the PPARs in the Diabetic Eye.Revisiting PPARγ as a target for the treatment of metabolic disorders The peroxisome proliferator-activated receptor-gamma regulates murine pyruvate carboxylase gene expression in vivo and in vitro.The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform PKCδ regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans.PPAR-gamma expression modulates insulin sensitivity in C2C12 skeletal muscle cells Hepatic glucose intolerance precedes hepatic steatosis in the male aromatase knockout (ArKO) mouse.PPARγ: a circadian transcription factor in adipogenesis and osteogenesis.Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation.Muscle as a "mediator" of systemic metabolism Beneficial effects of subcutaneous fat transplantation on metabolism Depletion of suppressor of cytokine signaling-1a causes hepatic steatosis and insulin resistance in zebrafish.Ginseng berry extract supplementation improves age-related decline of insulin signaling in mice.Respective contributions of maternal insulin resistance and diet to metabolic and hypothalamic phenotypes of progeny

P2860

Q24672153-CCA1FF73-E00C-4973-9327-77E7731E8F38 Q25257827-1696DE72-066A-4598-8E9D-CBB2D876C5CA Q26739984-83CD99CE-A3A6-4397-BCF2-D63148944F1F Q26749072-13BB1700-BE95-4D40-A672-14A2E7939D2A Q26825855-7AD58D36-0AD3-4BD7-9053-3DBA3E4EFC45 Q27310637-070E8C52-56A8-4729-BE6D-81A51A242046 Q28221639-3BE1630D-D434-4F58-88CF-FAC94D04CAEC Q28506039-AABA8995-E3E9-4EB2-9203-B2954029D0A9 Q33283063-6F302B76-2C59-43EA-A8F0-6B178607168E Q33577124-11C60DF2-C0E8-48AA-926D-0EDA93F97DA7 Q33624769-9ACAF696-A37F-4F1F-A268-4D0A0397A4A4 Q33656563-C55825C5-64CB-4AF4-8EF7-BAEF2C733090 Q33699001-01987DD7-8D9C-4234-8CA4-28E4F79A2948 Q33717836-14C623CE-E2CC-45F3-8E02-2B24D1DBD2F3 Q33751474-B9C76958-DD28-4FB9-8869-53DBC21AA4C7 Q34025180-A2C2A306-93BD-44EC-B853-6027C648B0C5 Q34094336-BE83A73F-6726-4865-9D7D-3B3A03FC5B1E Q34165847-4338097B-8038-436A-A40B-76D73D7863CE Q34166632-BE16986E-0694-401E-AF75-90B29E41B4C4 Q34178976-7E478612-DA74-4BB9-B913-A194EF1D38F5 Q34187966-DEA68B0E-B227-45D8-83AB-D6C82D5DEA2A Q34235817-62F470C6-FEF5-45F9-B9B1-E583F653617C Q34270996-57EB19EC-DA34-44CA-98D0-5683A94E0B10 Q34315432-6730A81D-1343-4037-B1B9-D0C4BDC7D3D3 Q34403650-7652E599-23A7-4ECB-84E4-A71209C1AC97 Q34416432-0A561AA1-1653-4B79-ABE4-ACBBBDD38801 Q34594935-B4A83CE5-A368-4CA2-8895-DD687553DC9C Q34798213-5514B9C4-810B-43E3-9691-3F73258C0CF4 Q35004507-69182B1C-B7F1-4C7D-9CB4-1957F9B6B787 Q35004514-0597A90D-A9DC-42C9-B4B6-0B012C3BBC6B Q35015769-92330EDA-E216-42E4-B30B-A89EE229DDEE Q35048456-2F1E2B20-13E2-47D2-8830-70E4044E7A6E Q35092619-E09DF102-5FC4-4648-B899-1B629B9CB97D Q35093192-22C522E1-B512-477F-AD78-4AA9B9292645 Q35131032-F9DBD927-9045-4E8C-A81D-20FF3A0BF226 Q35429223-C6A35462-3737-4370-A186-8DAF8318B4DC Q35485321-25C53C4E-EA32-4591-8471-25A885ED79FD Q35574951-9A3D83E5-03EB-4000-95A1-3BC5591600DC Q35586050-B3603A55-2076-4840-BEC9-8411500D04DC Q35602673-5FC8AFD8-A2D0-4FF4-A4BC-4E9532AEA4F8

P2860

Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.

http://www.wikidata.org/entity/Q35242884

description

2003 nî lūn-bûn

@nan

2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Muscle-specific PPARgamma-defi ...... respond to thiazolidinediones.

@ast

Muscle-specific PPARgamma-defi ...... respond to thiazolidinediones.

@en

type

label

Muscle-specific PPARgamma-defi ...... respond to thiazolidinediones.

@ast

Muscle-specific PPARgamma-defi ...... respond to thiazolidinediones.

@en

prefLabel

Muscle-specific PPARgamma-defi ...... respond to thiazolidinediones.

@ast

Muscle-specific PPARgamma-defi ...... respond to thiazolidinediones.

@en

P1433

Q35242884-02456792-D367-4E24-9458-D4A15173CEC2

P1476

Q35242884-6356265E-70C8-423D-8E55-1DBF27BB8157

P2093

Q35242884-0F85632E-169B-45A1-AA3E-458B92F9115E

Q35242884-285499D9-47D3-4FD3-835C-48FA5B53DF57

Q35242884-3FBB5AD2-6192-4E69-8723-B949B217C3F0

Q35242884-4103C1EC-98D4-4606-9ACE-B15BBA053483

Q35242884-594991BC-7E96-4D33-9228-188E68EDBFCD

Q35242884-A4C69E90-2D26-4E91-885A-012C980B657D

Q35242884-BEBD60AE-5916-43A9-BF76-A13D688F73AE

Q35242884-EECC72A4-3F12-4EC4-B9E8-D6F8645250F8

P2860

Q35242884-029C42D1-511F-43A9-A89D-4E827F5DE633

Q35242884-04B32BC3-8B71-4C9E-929B-27AF8BD4CCC6

Q35242884-04DC8308-1F54-4B94-8D7B-AF64AD79C3ED

Q35242884-07FFD401-BB3D-4A30-B88D-A3B93CDF5D0B

Q35242884-0AE5F43E-81B9-4FF1-A3EF-831FD24DFF08

Q35242884-0B5B7809-CBFB-4A8A-AD7D-A195E9A2B284

Q35242884-0C40CFD1-69FE-4F99-8584-9F979DEA644E

Q35242884-10173ECA-35B7-43A8-B5C5-36510C1C94FD

Q35242884-1530C8C9-C8EB-4BBF-83D0-2771B8A69FCF

Q35242884-2CC9DCB3-4B9C-4536-9362-2E2BA4B2A5CD

P304

Q35242884-580B08D6-15B7-4C3C-867B-CBCDCA4E1550

P31

Q35242884-AD08853D-21AF-4F94-92F8-19F49045F83E

P356

Q35242884-9B66FA48-7C63-426F-BBB5-B4ECB356F0E0

P407

Q35242884-FABD9026-C918-4767-8A69-089AFCE6FF64

P433

Q35242884-1BEF6353-6C61-4229-8EBA-8EAEC7D8BB76

P478

Q35242884-FF5B96DF-C577-4E92-8C90-3EF99F87A392

P50

Q35242884-077EE4D5-8827-4210-9ED1-1AE62E63C966

Q35242884-120E3E10-73C5-4D3D-A2F2-385B25D63F51

Q35242884-45D3C1F9-03D9-4E29-B2C7-6B2A911ECC4A

Q35242884-D3C67391-696F-4258-ADFC-A400904025FB

P577

Q35242884-AE407370-7066-4519-9E96-947707296C02

P698

Q35242884-F208BCDB-35ED-4E96-8047-9ED7BD273BC5

P921

Q35242884-FE7873AC-673F-4E5E-AE2F-46CF64B63B92

P932

Q35242884-3FF12C9E-78F4-4DAE-9407-DA9CF1008D0E

P356

P1433

Journal of Clinical Investigation

P1476

Muscle-specific PPARgamma-defi ...... respond to thiazolidinediones.

@en

P2093

Alison C Jozsi

http://www.w3.org/2001/XMLSchema#string

Evan D Rosen

http://www.w3.org/2001/XMLSchema#string

Frank J Gonzalez

http://www.w3.org/2001/XMLSchema#string

Ildiko Szanto

http://www.w3.org/2001/XMLSchema#string

Laurie J Goodyear

http://www.w3.org/2001/XMLSchema#string

Lihong Chen

http://www.w3.org/2001/XMLSchema#string

Michael F Hirshman

http://www.w3.org/2001/XMLSchema#string

Simon J Fisher

http://www.w3.org/2001/XMLSchema#string

P2860

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4

Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target

Troglitazone action is independent of adipose tissue

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)

P304

608-618

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI17305

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Bruce Spiegelman

Andrew W Norris

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12925701

http://www.w3.org/2001/XMLSchema#string

P921

P932

171387

http://www.w3.org/2001/XMLSchema#string